Serum Transthyretin as Prognostic Biomarker for Cardiovascular Events and Mortality
Serum TTR is a predictor of CV events, all-cause and CV mortality, and HF across different populations, underscoring its potential use as a CV biomarker and instigating research on the possible clinical role of TTR medications in other clinical settings other than amyloidosis.
Authors
- Georgios Lazaros
- N. Ioakeimidis (ORCID: https://orcid.org/0000-0001-7344-2828)
- Dimitrios G. Terentes-Printzios (ORCID: https://orcid.org/0000-0003-4039-8263)
- Alexandros Kasiakogias (ORCID: https://orcid.org/0000-0002-1090-4965)
- Konstantinos P Tsioufis (ORCID: https://orcid.org/0000-0002-7636-6725)
- Themistoklis Katsimichas
- Alexios Antonopoulos (ORCID: https://orcid.org/0000-0001-9137-0143)
- Polyxeni Alexiou (ORCID: https://orcid.org/0009-0006-3481-8662)
- Theodoros Tsampras (ORCID: https://orcid.org/0009-0004-0841-1688)
- Charalambos Vlachopoulos
- Freideriki Eleni Kourti
- Maria Eleni Koilakou (ORCID: https://orcid.org/0009-0001-4589-7822)
Institutions
- National and Kapodistrian University of Athens (GR)
- Eginition Hospital (GR)
- Hippocration General Hospital (GR)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102208
- Citations
- 1
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 1.63